IXHL — Incannex Healthcare Income Statement
0.000.00%
- $121.14m
- $106.10m
- $0.09m
Annual income statement for Incannex Healthcare, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
R2021 June 30th | 2022 June 30th | R2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | 10-K | 10-K | 10-K |
| Standards: | IFRS | IFRS | USG | USG | USG |
| Status: | fx Final | fx Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.47 | 0.572 | 0 | 0.012 | 0.086 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 9.95 | 11.4 | 49.7 | 30.1 | 25.3 |
| Operating Profit | -8.48 | -10.8 | -49.7 | -30 | -25.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.48 | -10.8 | -48.8 | -18.4 | -46.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.48 | -10.8 | -48.8 | -18.5 | -46.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.48 | -10.8 | -48.8 | -18.5 | -46.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.48 | -10.8 | -48.8 | -18.5 | -46.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.009 | -0.009 | -0.875 | -1.14 | -1.32 |